Episode 4 of 4 - Practical Strategies for Preventing and Mitigating Toxicities of Targeted Therapy

Despite advances with targeted therapies, adverse events (AEs) must be identified and managed for optimal treatment response, clinical outcomes, and quality of life for patients with non-small cell lung cancer (NSCLC). Join us for the final episode of the 4-part educational initiative Biomarker-based Therapy for NSCLC:  Improving Collaboration, Communication, and Care, in which our expert faculty have a candid conversation about mitigating common AEs associated with targeted therapies and provide strategies for engaging underserved patients in the prevention and monitoring of these potential toxicities.